CalciMedica, Inc. announced that stockholders approved several key proposals at its 2026 Annual Meeting of Stockholders held on August 19, 2026. The approved measures include authorizing a reverse stock split, significantly increasing the number of shares available under its equity incentive plan, and approving the issuance of warrants related to a prior securities purchase agreement.
Key Details
- Reverse Stock Split: Stockholders approved an amendment to the Company's Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 and 1-for-10, to be determined by the Board of Directors.
- Equity Incentive Plan Expansion: An amendment to the 2023 Equity Incentive Plan was approved, increasing the number of shares of common stock authorized for issuance by 7,500,000.
- Warrant Issuance Approval: Stockholders approved the issuance of Series A and Series B Warrants to purchase up to an aggregate of 37,346,858 shares of common stock, related to a Securities Purchase Agreement dated June 23, 2026.
- Director Election: Allan Shaw and Robert N. Wilson were elected as Class III directors to serve three-year terms until the 2029 annual meeting.